延长来曲唑辅助治疗时间降低早期乳腺癌绝后患者复发风险.pdfVIP

MA.17R:ReducedRiskofRecurrence

WithExtendingAdjuvantLetrozole

Beyond5YrsinPostmenopausal

WomenWithEarly-StageBreast

Cancer

CCOtConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisantmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,

Incyte,Merck,andTaihoPharmaceuticals.

MA.17RExtendedLetrozole:Study

Background

▪5yrsofAItherapy,eitherinitiallyorafter2-5yrsoftamoxifen,

standardofcareforpostmenopausalwomenwithHR-positive

earlybreastcancer

▪BasedlargelyonresultsofCanadianCancerTrialsGroup

MA.17trial,whichcompared5yrsofletrozolevscebo

following5yrsoftamoxifen[1,2]

▪DFSandOSessuperiorwithletrozole

▪ExtendingAItreatmentwithletrozoleto10yrsmayfurther

reduceriskofbreastcancerrecurrence

▪Randomized,double-blind,cebo-controlledMA.17Rtrial

designedtotestefficacyofextendingAItreatmentwithletrozole

outto10yrs[3]

1.GossPE,etal.NEnglJMed.2003;349:1793-1802.2.JinH,etal.JClin

Oncol.2012;30:718-721.3.GossPE,etal.ASCO2016.LBA1.Slidecredit:

MA.17R:StudyDesign

Stratificationbylymphnodestatusat

diagnosis,prioradjuvantchemotherapy,

intervalweenlastAIdoseand

randomization,durationofpriortamoxifen

PostmenopausalptswithLetrozole2.5mgPOQD

ER+and/orPgR+breastfor5yrsFollow-up

cancerwhocompleted(n=959)

4.5-6yrsofletrozole